Development Program Reports. AstraZeneca shall keep the JDC regularly informed of the progress of its efforts to Develop Candidate Drugs in the Field and in Schizophrenia in the Territory. Without limiting the generality of the foregoing, AstraZeneca shall, on at least [********], provide the JDC and Targacept with reports. Such reports shall include [********]; provided, however, that in no event shall AstraZeneca be required to include [********] in such reports [********]. Targacept shall, on at least [********], or as may otherwise be provided in the applicable Product Development Plan, provide the JDC and AstraZeneca with reports in reasonable detail regarding the status of the Ongoing Ispronicline Trial and all Targacept Development Activities, including the rate of spending compared to the applicable budget for such Targacept Development Activities, and such additional information known to Targacept as may be reasonably requested from time to time by the JDC or AstraZeneca. For purposes of clarity, if either Party is required pursuant to this Section 5.9.1 to provide a report, summary, results or information to the other Party and provides such report, summary, results or information to the representatives of the other Party on the JDC, such providing Party shall thereupon also be deemed to have provided such report, results or information to the other Party pursuant to this Section 5.9.1. In addition, AstraZeneca shall provide Targacept with written notice of any Major Metabolites of any Collaboration Compound, Candidate Drug or Additional Compound that are Known to AstraZeneca.
Development Program Reports. Each Party shall keep the JPT generally informed of the progress of its efforts to Develop Clinical Candidates in the Territory. Without limiting the generality of the foregoing, each Party shall, on at least a [***], provide the JPT with reports in reasonable detail regarding the status of all preclinical IND-enabling studies and activities (including toxicology and pharmacokinetic studies), clinical trials and other activities conducted by or on behalf of each Party under the Development Program with respect to any Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 55 Development Lead or Clinical Candidate that is being Co-Developed or is eligible for Co-Development, or any Co-Developed Product, together with such additional information in its possession as may be reasonably requested from time to time by the JPT.
Development Program Reports. Subject to 4.10.2, MERCK shall keep the JSC regularly informed of the progress of its efforts to Develop Development Candidates in the Field in the Territory. Without limiting the generality of the foregoing, MERCK shall, at least once each [***], provide the JSC with reports in reasonable detail regarding the status of all preclinical IND-enabling studies and activities (including toxicology and pharmacokinetic studies), clinical trials and other activities conducted under the Development Program; provided, that, for so long as ARCHEMIX is obligated to perform ARCHEMIX Development Activities or has in effect a Co-Development Option with respect to a Product, (a) MERCK shall provide the JSC with the reports described above at least once each [***] and (b) ARCHEMIX and MERCK shall, not less than once each [***], provide the JSC with reports in reasonable detail regarding the status of all Development Activities and such additional information that they have in their possession as may be reasonably requested from time to time by the JSC.
Development Program Reports. MERCK shall keep the JSC regularly informed of the progress of its efforts to Develop Development Candidates in the Field in the Territory. Without limiting the generality of the foregoing, MERCK shall, at least once each [***], provide the JSC with reports in reasonable detail regarding the status of all preclinical IND-enabling studies and activities (including toxicology and pharmacokinetic studies), clinical trials and other activities conducted under the Development Program; provided, that, for so long as ARCHEMIX is obligated to perform ARCHEMIX Development Activities, (a) MERCK shall provide the JSC with the reports described above at least once each [***] and (b) ARCHEMIX and MERCK shall, not less than once each [***], provide the JSC with reports in reasonable detail regarding the status of all Development Activities and such additional information that they have in their possession as may be reasonably requested from time to time by the JSC.
Development Program Reports. Each Party shall keep the JLT generally informed of the progress of its efforts to Develop the Product. Before, during or after any JLT meeting, ELAN and WARATAH will provide the JLT with copies of any presentations or summaries that they have each created relating to their activities performed in connection with the Development Program. ("deleted text").
Development Program Reports. DS shall keep the JEC regularly informed of the progress of its efforts to Develop Licensed Products in the Field and in the Territory. Without limiting the generality of the foregoing, DS shall, at least once each six (6) months of each Calendar Year, provide the JEC with reports in reasonable detail regarding the status of all preclinical IND-enabling studies and activities (including toxicology and pharmacokinetic studies), clinical trials and other activities conducted under the Development Program. In addition, DS shall designate a senior member of its Development organization (who may be the DS Alliance Manager if the DS Alliance Manager is a senior member of the DS Development organization) with responsibility for the Development of Licensed Products to act as a liaison with ARQULE and who shall respond to inquiries from ARQULE on Development activities and progress.
Development Program Reports. Each Party shall keep the JDC regularly informed of the progress of its efforts to Develop Licensed Products in the Field in the Territory. Without limiting the generality of the foregoing, each Party shall, on at least a quarterly basis, provide the JDC with reports in reasonable detail regarding the status of all Clinical Trials, Manufacturing Development and other activities conducted under the Development Program, together with all raw data and results generated in each such Clinical Trial and such additional information that it has in its possession as may be reasonably requested from time to time by the JDC.
Development Program Reports. Each Party shall keep the JEC regularly informed of the progress of its efforts to Develop Licensed Products in the Field in the Territory. Without limiting the generality of the foregoing, ARQULE shall, on at least a monthly basis, and DS shall, once each Calendar Quarter, provide the JEC with reports in reasonable detail regarding the status of all Clinical Trials, Manufacturing Development and other activities conducted under the Development Program, together with all raw data and results generated in each such Clinical Trial and such additional information that it has in its possession as may be reasonably requested from time to time by the other Party.
Development Program Reports. The Responsible Party shall keep the JDC and the Participating Party regularly informed of the progress of its efforts to Develop Products in the Field in the Territory. Without limiting the generality of the foregoing, the Responsible Party shall, on at least a quarterly basis, provide the JDC with reports in reasonable detail regarding the status of all preclinical IND-enabling studies and activities (including toxicology and pharmacokinetic studies), Clinical Trials, Manufacturing Development and other activities conducted under the Development Program, together with all raw data and results generated in each such preclinical IND-enabling study and/or activity, Clinical Trial and such additional information that it has in its possession as may be reasonably requested from time to time by the JDC. The Participating Party shall, on at least a quarterly basis, provide the JDC with reports in reasonable detail regarding the status of all Development Activities of the Participating Party and such additional information that it has in its possession as may be reasonably requested from time to time by the JDC.
Development Program Reports. Each Party shall keep the JLT generally informed of the progress of its efforts to Develop the Product. Before, during or after any JLT meeting, ELAN and WARATAH will provide the JLT with copies of any presentations or summaries that they have each created relating to their activities performed in connection with the Development Program. If WARATAH has not elected to opt out under Section 3.8.6(b), ELAN shall provide WARATAH with Phase I Clinical Trial data, Phase II Clinical Trial data, Phase III Clinical Trial data and, if reasonably requested by WARATAH, other results, other than CMC Section data (with respect to CMC Section data ELAN will provide monthly development status reports on CMC Section related activities).
